CA 19-9 tumor marker: is it reliable? A case report in a patient with pancreatic cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Retrospective analysis of preoperative tumor marker levels in rectal cancer patients: Implications for diagnosis.World journal of gastrointestinal surgery · 2025
   Article
2. Elevation of the tumor marker CA19-9 in a pancreatic cancer survivor with benign prostatic hyperplasia: A clinical case report.Clinical case reports · 2024
   Article
3. Targeted Nanoparticle-Based Diagnostic and Treatment Options for Pancreatic Cancer.Cancers · 2024
   Review
4. Advances in biomarkers and techniques for pancreatic cancer diagnosis.Cancer cell international · 2022
   Review
5. Circulating Biomarkers for Therapeutic Monitoring of Anti-cancer Agents.The oncologist · 2022
   Review
6. Circulating Nucleic Acids as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma.Cancers · 2022
   Review
7. Low Carbohydrate Antigen 19-9 (CA 19-9) Levels in a Patient Highly Suspected of Having Caput Pancreas Tumor.Cureus · 2022
   Article
8. Humoral Predictors of Malignancy in IPMN: A Review of the Literature.International journal of molecular sciences · 2021
   Review
9. Exosomal biomarkers for cancer diagnosis and patient monitoring.Expert review of molecular diagnostics · 2020
   Review
10. Exploiting the relevance of CA 19-9 in pancreatic cancer.Journal of cancer metastasis and treatment · 2020
    Article
11. CA 19-9 and pancreatic cancer.Clinical advances in hematology & oncology : H&O · 2013
    Article

Corrections and comments

• Commented on by
  CA 19-9 and pancreatic cancer.2013

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as